Antiinflammatory and anticoagulative agents in COVID-19 pneumonia treatment

Combination therapy of Dexamethasone and Enoxoparin promotes SARS-CoV-2 pneumonia recovery - Steroids and LMWH in SARS-CoV-2 pneumonia treatment

Status

Active, not recruiting

Phases

Unknown

Study type

Observational

Source

JPRN

Registry ID

JPRN-UMIN000042489

Enrollment

157

Registered

2020-11-18

Start date

2020-04-08

Completion date

Unknown

Last updated

2026-06-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Completed

Interventions

None listed

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: CT abnormalities (CT score 1-4), anticoagulant therapy, no contradiction for dexamethasone

Exclusion criteria

Exclusion criteria: Dexamethasone intake for prior 6 month, anti-interleukin drugs admission

Design outcomes

Primary

Measure	Time frame
Dexamethasone therapy in SARS-CoV-2 patients significantly improved CT score and appear to decrease mortality rate.	—

Countries

Europe

Contacts

Public ContactPetr Tkachenko

Clinic of internal diseases propedeutics, gastroenterology, and hepatology, I.M. Sechenov First Mosc Internal Medicine

dr.ptk@mail.ru0079166776451

Outcome results